Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of retinaldehyde, niacinamide, and haritaki fruit extract is a dermocosmetic anti-aging formulation developed by Pierre Fabre under the Avène brand, specifically within the Hyaluron Activ B3 line. The formulation typically contains 0.1% retinaldehyde, 2% niacinamide, and 0.1% haritaki fruit extract. Retinaldehyde serves as a direct precursor to retinoic acid, promoting cellular renewal and collagen synthesis to reduce wrinkles. Niacinamide (Vitamin B3) enhances skin barrier function and provides anti-inflammatory benefits. Haritaki fruit extract (*Terminalia chebula*) acts as an antioxidant and is included for its potential to inhibit hyaluronidase, thereby preserving natural hyaluronic acid levels in the skin. Clinical data indicates the combination is effective in improving skin firmness, texture, and radiance, and is used to maintain results following aesthetic procedures like hyaluronic acid fillers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on retinaldehyde + niacinamide + haritaki fruit extract.